Active Ingredient History
Bupropion, an antidepressant of the aminoketone class and a non-nicotine aid to smoking cessation, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Compared to classical tricyclic antidepressants, Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine, serotonin, and dopamine. In addition, Bupropion does not inhibit monoamine oxidase. Bupropion produces dose-related central nervous system (CNS) stimulant effects in animals, as evidenced by increased locomotor activity, increased rates of responding in various schedule-controlled operant behavior tasks, and, at high doses, induction of mild stereotyped behavior. Bupropion is marketed as Wellbutrin, Zyban, and generics. Bupropion is indicated for the treatment of major depressive disorder (MDD). WELLBUTRIN, WELLBUTRIN SR, and WELLBUTRIN XL are not approved for smoking cessation treatment, but bupropion under the name ZYBAN is approved for this use. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 3)
Alcohol Drinking (Phase 2)
Alcoholism (Phase 4)
Alcohol-Related Disorders (Phase 3)
Alzheimer Disease (Phase 3)
Amphetamine-Related Disorders (Phase 2)
Angina, Unstable (Phase 4)
Anhedonia (Phase 2)
Anxiety Disorders (Phase 3)
Apathy (Phase 4)
Asthma (Phase 4)
Bariatric Surgery (Phase 4)
Behavior, Addictive (Phase 2)
Binge Drinking (Phase 2)
Binge-Eating Disorder (Phase 2/Phase 3)
Bipolar Disorder (Phase 4)
Blood Pressure (Phase 4)
Breast Neoplasms (Phase 4)
Cancer Survivors (Phase 3)
Cannabis (Phase 4)
Carcinoma (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Cardiovascular Diseases (Phase 4)
Central Nervous System Stimulants (Early Phase 1)
Cigarette Smoking (Phase 4)
Cocaine-Related Disorders (Phase 2/Phase 3)
Cognition (Early Phase 1)
Counseling (Phase 1/Phase 2)
Crohn Disease (Phase 2/Phase 3)
Deficiency Diseases (Phase 4)
Dementia (Phase 3)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Drug Interactions (Phase 1)
Dysthymic Disorder (Phase 4)
Endometrial Neoplasms (Phase 2)
Epilepsy (Phase 3)
Erectile Dysfunction (Phase 2)
Esophageal Neoplasms (Phase 2)
Fatigue (Phase 4)
Feeding and Eating Disorders (Phase 2/Phase 3)
Friedreich Ataxia (Phase 4)
Gambling (Phase 2)
Gastric Bypass (Phase 4)
Glioma (Phase 3)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 4)
Heart Diseases (Phase 1)
Hepatolenticular Degeneration (Phase 1)
HIV (Phase 3)
HIV Infections (Phase 2)
Huntington Disease (Phase 2)
Inflammatory Bowel Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 3)
Marijuana Abuse (Phase 2)
Medication Adherence (Phase 4)
Melanoma (Phase 1)
Mental Disorders (Phase 4)
Metabolism (Phase 1)
Methamphetamine (Phase 2)
Mitochondrial Diseases (Phase 1)
Mood Disorders (Phase 1)
Myocardial Infarction (Phase 4)
Neoplasms (Phase 3)
Neoplasms, Second Primary (Phase 2)
Obesity (Phase 4)
Obesity, Morbid (Phase 4)
Opioid-Related Disorders (Phase 3)
Ovarian Neoplasms (Phase 2)
Overweight (Phase 3)
Pancreatic Neoplasms (Phase 2)
Pharmacogenetics (Phase 2)
Pharmacokinetics (Phase 1)
Postmenopause (Phase 2)
Pregnancy (Phase 2)
Pregnancy Complications (Phase 4)
Psychomotor Agitation (Phase 3)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Recurrence (Early Phase 1)
Remission Induction (Phase 3)
Renal Insufficiency, Chronic (Phase 3)
Restless Legs Syndrome (Phase 2/Phase 3)
Schizophrenia (Phase 4)
Seasonal Affective Disorder (Phase 3)
Sexual Dysfunction, Physiological (Phase 4)
Sexual Dysfunctions, Psychological (Phase 2/Phase 3)
Sexual Health (Phase 1/Phase 2)
Sleep Disorders, Intrinsic (Phase 4)
Sleep Wake Disorders (Phase 4)
Smokers (Phase 4)
Smoking (Phase 4)
Smoking Cessation (Phase 4)
Stomach Neoplasms (Phase 2)
Stress Disorders, Post-Traumatic (Phase 4)
Stroke (Phase 2)
Substance-Related Disorders (Phase 4)
Substance Withdrawal Syndrome (Phase 2/Phase 3)
Suicidal Ideation (Phase 4)
Suicide (Phase 4)
Suicide, Attempted (Phase 2/Phase 3)
Therapeutic Equivalency (Phase 1)
Tobacco, Smokeless (Phase 3)
Tobacco Smoking (Phase 4)
Tobacco Use (Phase 3)
Tobacco Use Cessation (Phase 4)
Tobacco Use Disorder (Phase 4)
Tuberculosis (Phase 1)
Tuberculosis, Pulmonary (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
